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Background: Topical Minoxidil is the most common FDA approved treatment for Androgenic 
Alopecia (AA), but does not work for everyone. Platelet rich plasma (PRP) therapy is a new 
treatment for AA that has been shown to be effective at treating AA. However, there is no 
consensus on which treatment is more effective. 
 
Purpose: The purpose of this systematic review is to compare the studies available that directly 
evaluate whether PRP therapy or topical Minoxidil is more effective at treating AA. 
 
Methods: The google scholar database was searched for studies written in English that directly 
compared platelet rich plasma injections and topical minoxidil in treatment of AA. Ultimately 4 
studies were included in this review. 
 
Results: Patel et al (2016) showed the PRP group having better outcomes. In Verma et al (2019) 
the PRP group had higher patient satisfaction and perceived better outcomes. In Novarro et al 
(2016) the PRP group had a higher increase in anagen hair and higher decrease in telogen hair. In 
Farid et al (2016) the Minoxidil group had a higher rate of normalization of hair shedding than 
PRP group.  
 
Discussion: All 4 studies found both treatments effective at treating androgenic alopecia. The 
studies showed increases in hair density and amount of anagen hair present with both treatments 
and no serious side effects. In the future, more studies are needed to fully evaluate if PRP 
therapy is more effective than topical Minoxidil at treating AA. 
 
Conclusion: This study shows that there is no clear evidence that PRP or Minoxidil is more 
effective than the other at treating AA.  
 











Androgenic Alopecia (AA) is the most common form of hair loss and affects 50 million 
men and 30 million women in the United States alone1. Americans, it is estimated, spend more 
than $3.5 billion on various hair regrowth treatments a year to treat hair loss2.  People affected 
with AA can suffer from psychological and emotional distress and have a decreased quality of 
life3-6. It is estimated that 50% of men by age 50, and 40% of women by age 70 – 79 will suffer 
from some form of hair loss7,8. AA has the highest incidence in Caucasians, followed by Asians 
and then Africans9. It is believed to be genetically determined with family history being a big 
risk factor10. Up to 15 loci have been associated with contributing to AA with the androgen 
receptor on the X chromosome showing the strongest association11,12. For both men and women 
AA is thought to be caused by a process called follicular miniaturization7. In men, a metabolite 
of testosterone, dihydrotestosterone (DHT), binds to androgen receptors in the hair follicle. This 
leads to a gradual transformation of the follicle from producing a thick terminal hair with a long 
lifespan to a thinner vellus hair with a shorter lifespan13. The process starts out as bitemporal 
regression and thinning at the vertex which can progress to full hair loss throughout the top of 
the scalp and can be measured by the Hamilton-Norwood scale13,14. In women the mechanism of 
action for follicular miniaturization and the role of androgens is not yet fully understood15. 
Female patterned hair loss is characterized by an evenly distributed thinning of the hair with no 
discernable pattern and can be measured by the Ludwig classification16,17.  
Currently there are only two FDA approved treatments for AA. Oral Finasteride is 
approved in men and topical Minoxidil is approved for both men and women18. Both 
medications need to be used daily and are not covered by insurance due to the fact that 
androgenic alopecia treatment is considered cosmetic, and therefore the patient must pay out of 
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pocket19. Of the two, topical Minoxidil is more common because it is relatively cheap, well 
tolerated, and can be purchased over the counter20, 21. It is a liquid or foam that is applied directly 
to the scalp and thought to work by causing vasodilation21. Having more blood brings more 
nutrients to the hair follicle and stimulates dermal papilla cells by promoting stem cells to release 
growth factors22,23. Both processes help keep the hair follicle healthy. Studies have shown that 
Minoxidil is an effective treatment for AA with most people showing an increase in hair density 
with daily use22-24. However, it has been documented that Minoxidil does not work for 
everyone24. 
A relatively new non FDA approved treatment for AA, which provides a potential 
attractive alternative to topical minoxidil, is platelet rich plasma (PRP) therapy. PRP therapy is a 
minimally invasive procedure with limited side effects that does not require daily use. For this 
treatment a small amount of a patient’s blood is taken, spun down in a centrifuge, and layers 
separated until the PRP is isolated. Then the PRP is injected into the scalp intradermally. The 
mechanism for how this helps hair growth is not fully understood. It is thought that platelets 
contain many growth factors, cytokines, and chemokines that help promote hair growth and hair 
maturation25. Patients have been shown to have an increase in hair density after treatment when 
compared to a placebo25-27.  
Before recommending a new treatment like PRP it is important to establish whether that 
treatment is just as effective or more effective than the current treatment options. The current 
evidence available shows that both topical minoxidil and PRP therapy are effective at treating 
AA. However, there is no consensus on which treatment is more effective. The purpose of this 
analysis is to compare the studies available that directly compare whether PRP therapy or topical 





I carried out my search of the google scholar database using the PRISMA guidelines. My 
search terms used were Androgenetic Alopecia, platelet, Minoxidil, and versus with the time 
period set at 2015 – 2019, excluding patents and citations. The search returned a total of 272 
results. I was searching for studies written in English that directly compared platelet rich plasma 
injections and topical minoxidil in treatment of AA. I excluded studies that looked at any other 
form of alopecia other than AA, used only 1 intervention of interest, combined treatment 
modalities, not looking at adult men and women, and not written in English. I found a total of 6 
studies that met my inclusion criteria. Of those 6, 4 were ultimately included in this systematic 
review. Of the 2 excluded, 1 study is a very recent study where only an abstract is available and 
































Patel et al (2016) included 220 males aged 20 – 50 years old who had been diagnosed 
with androgenic alopecia grade II – VII on the Norwood – Hamilton scale. These 220 males 
were randomized using the simple sampling method into two groups of 110 individuals. One 
group received daily topical minoxidil treatment for 6 months and the other group received 6 
PRP injections every 15 days for a period of 3 months. Photographs were taken and analyzed for 
hair distribution pattern and hair density and diameter were measured before treatment began and 
once treatment was discontinued. Comparing the before and after for both groups the researchers 
rated the improvement of each patient as good, fair, and poor. They found that overall PRP 
therapy had a more positive effect on hair regrowth than Minoxidil. Using a Chi square test 
between the PRP group and Minoxidil group, they calculated a P-value of 0.000647. The greatest 
effect was seen in those aged 20 – 30 with the lesser duration of hair loss28. 
Verma et al (2019) included 40 males aged 20 – 49 years old who had been diagnosed 
with AA grade I -V on the Hamilton – Norwood scale and had not used any hair regrowth 








282 PRP (213 Women 69 Male)
97 5% Minoxidil (65 Male 32 Female)
40
20 PRP with microneedling (16 female 4 male)
20 5% Minoxidil (15 female 5 male)
Patel (2016) Randomized Control Trial
        20 - 50 year old males.      
Grade II - VII Norwood Hamilton 
Scale
Type of Hair: Terminal or Vellus, Density, 
Calibre (course, fine, color). Degree and 
pattern of hair loss
            20 - 49 year old males.        
Grade I - V Norwood Hamilton Scale
Verma (2019) Randomized Control Trial
Global photography, Hair pull test, Patient 
standardized hair growth questionnaire, 
patient satisfaction score
Farid (2016) Randomized Control Trial
40 patients who met criteria of 
having PHL. Any grade of the 
Norwood Hamilton Scale or Savin 
Upgrade of level on severity scale. Patient 
satisfaction score. Count of hair density in 
1cm2 area. Rate of hair shedding.
Navarro (2016) Randomized Control Trial
Standardized Trichograms: Anagen to 
Telogen ratio, overall improvement
   29 - 75 year old male or female 
Grade I - V Norwood Hamilton Scale 
Grade I - II Ludwig Scale
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treatment over the past 6 months. The 40 males were randomly divided into two groups of 20. 
Group A received monthly intradermal PRP injections for 4 months while group B used 1mL 
topical 5% Minoxidil twice daily for 6 months. Group A was followed up every month for 6 
months while group B was followed up every 3 months for 6 months. At each follow up, 
assessment was done using global photography, hair pull test, patient standardized hair growth 
questionnaire, and patient satisfaction score. For all quantitative variables mean and standard 
deviations were calculated using Epi-info version 7 and an unpaired T test was applied. This 
study found that group A had more subjects with positive outcomes in the hair pull test, hair 
growth questionnaire, and patient satisfaction score. Only a few measurements were statistically 
significant. More patients (8 of 16) in group A felt they had moderate hair regrowth compared to 
group B (1 of 14), P-value 0.014. When asked how they feel about the appearance on the crown 
of their head more patients in group A were satisfied (14 of 16 to 5 of 14, P-value 0.004) and less 
patients were neutral (2 of 16 to 7 of 14, P-value 0.03) when compared to group B. Lastly, the 
subject’s patient satisfaction score was higher in group A (6.56 ± 1.09) than group B (4.85 ± 
1.46), P-value 0.001. In group A four patients dropped out of the study due to pain with PRP 
injections. Six patients dropped out of the study from group B due to no observed positive effects 
from Minoxidil treatment29. 
Navarro et al (2016) included 379 patients (245 women and 134 men) diagnosed with AA 
who had previously underwent topical minoxidil or platelet rich plasma injections between 2012 
– 2014 at the Dermatology and Aesthetic center in Valencia Spain. Women must be grade I – II 
on the Ludwig scale and males must be grade I – V on the Hamilton – Norwood scale. 282 
participants (213 women and 69 men) received a PRP injection once a month for 2 months and 
97 participants (65 men 32 women) were treated with 1 mL 3% Minoxidil solution 6 nights a 
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week for 4 months. Photographs and diagnostic trichograms were taken before and 4 months 
after beginning treatment. The distribution of qualitative variables was analyzed using the 
Shapiro-Wilk test and the anagen-telogen ratio between pre and post treatment was analyzed 
using the Wilcoxon non parametric test. They found that patients in the PRP therapy group 
showed a higher increase in anagen hair, 6.9% ± 0.4% to 4.6%± 0.5% p value < 0.05, and a 
higher decrease in telogen hair, 5.7% ± 0.3% to 2.6% ± 0.5% p value < 0.05 when compared to 
the minoxidil therapy group. In addition, global photography showed a bigger improvement in 
volume of hair in the PRP group30.  
Farid et al (2016) included 40 patients (31 female, 9 male) who had been diagnosed with 
AA between April 2012 – December 2014 at the Alexandria Main University Hospital in Egypt. 
The patients were then randomly divided into two groups of 20. Group 1 received PRP injections 
once a month for 6 months, while group 2 received 1mL topical 5% Minoxidil applied twice 
daily for 6 months. Photographs were taken to determine hair distribution patterns and non 
vellous hair counting in a 1cm^2 area of the scalp before and after treatment while also 
measuring patient satisfaction and rate of hair shedding once treatment was finished. To compare 
the two groups Chi-square, fisher’s exact, and Mann-Whitney tests were used. They found both 
treatment modalities were comparable in their effectiveness at improving hair density and 
alopecia grade. The study found slightly more positive outcomes in topical minoxidil, with only 
1 measurement being statistically significant. When comparing hair shedding 19 of 20 patients in 
the Minoxidil group compared to 13 of 20 patients in the PRP group had a normalization of hair 





In the four studies analyzed, three of the four found a more positive outcome in patients 
treated with PRP therapy28-30. While only one study found topical Minoxidil was associated with 
more positive outcomes, the difference between the two treatments was not statistically 
significant31. All 4 studies found both treatments effective at treating androgenic alopecia. The 
studies showed increases in hair density and amount of anagen hair present with both treatments 
and no serious side effects. Looking at the current studies available there is no clear evidence 
that PRP therapy or topical Minoxidil is more effective over the other at treating AA. Although 
recent studies have shown that using a combination therapy approach to treating AA is superior 
to monotherapy. Two studies found that finasteride combined with minoxidil had superior 
outcomes to minoxidil alone32,33. In addition, a recent study by Shah et al (2017) showed PRP 
therapy combined with minoxidil had superior outcomes to minoxidil alone34. 
Limitations of this systematic review include limited number of studies to analyze, no 
uniform scale to evaluate improvement of hair loss, and no standard protocol for PRP therapy to 
treat androgenic alopecia. Three of the four studies mainly relied on subjective data with patient 
questionnaires and investigator grading of photographs. With the small sample sizes the 
variability in which subjects view their treatment could impact which treatment is viewed as 
superior. In addition, PRP injections are a relatively new therapy for treating AA and there is not 
a consensus on which protocol to use. There are many protocol variations, differences include 
anticoagulant used, starting amount of blood, centrifugation technique, concentration of platelets, 
and whether an activator is used or not. While there is no consensus of which protocol is 
superior, each study used a different protocol which could affect the outcome of the 
treatment35,36. In Farid et al (2016) the study also used micro needling in conjunction with PRP 




 In the future, more studies are needed to fully evaluate if PRP therapy is more effective 
than topical Minoxidil at treating AA. These future studies should involve more subjects in 
similar stages of hair loss, longer duration of treatment, and a standard protocol for PRP therapy 
to fully evaluate the two treatments. This study shows that both topical minoxidil and PRP 
therapy can be effective at treating AA, but there is no evidence to suggest that PRP therapy 
should be recommended to patients over topical Minoxidil. As therapies improve more studies 
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